The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|May 9, 2019
HPC Binder Designed for Small Tablets
Author(s)Pharmaceutical Technology Editors
Ashland introduces Klucel EXF Ultra HPC, a low friability, high strength binder.
Advertisement
Ashland has introduced Klucel EXF Ultra HPC, a tablet binder that was developed to enable drug manufacturers to use smaller-size tablets for patients that have challenges swallowing. The announcement was made in an April 30, 2019 press statement.
The hydroxypropyl cellulose (HPC) excipient has exceptional binder efficiency, compressibility, and plasticity with enhanced tablet strength and low friability at usage levels as low as 1–2%, the company reports. The HPC also features an ultra-fine particle size and is designed to enhance hardness and improve friability, which may reduce defect rates.
Ashland reports that the company introduced HPC more than 65 years ago; the Klucel brand has been used for direct compression and dry granulation. The latest version of the HPC was designed to improve manufacturing costs and patient-centric drug delivery by improving tablet binding effectiveness.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement